Workflow
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates
ARMPArmata Pharmaceuticals(ARMP) ZACKS·2024-11-13 23:20

Group 1 - Armata Pharmaceuticals reported a quarterly loss of 0.15pershare,betterthantheZacksConsensusEstimateofalossof0.15 per share, better than the Zacks Consensus Estimate of a loss of 0.28, and an improvement from a loss of 0.31pershareayearago,resultinginanearningssurpriseof46.430.31 per share a year ago, resulting in an earnings surprise of 46.43% [1] - The company posted revenues of 2.97 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 230.33%, compared to revenues of 1.23millioninthesamequarterlastyear[2]−ArmataPharmaceuticalshassurpassedconsensusrevenueestimatestwotimesoverthelastfourquarters[2]Group2−Thestockhasunderperformed,losingabout15.11.23 million in the same quarter last year [2] - Armata Pharmaceuticals has surpassed consensus revenue estimates two times over the last four quarters [2] Group 2 - The stock has underperformed, losing about 15.1% since the beginning of the year, while the S&P 500 has gained 25.5% [3] - The current consensus EPS estimate for the coming quarter is -0.29 on revenues of 1.13million,andforthecurrentfiscalyear,itis−1.13 million, and for the current fiscal year, it is -1.02 on revenues of $3 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 26% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]